5-Azacytidine in myelodysplastic syndromes: A clinical practice guideline

Cancer Treatment Reviews

Volumn 37, Issue 2, 2011, Pages 160-167

  Buckstein, Rena ^a,b   Yee, Karen ^b,c   Wells, Richard A ^a,b,d  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d Canada   (Canada)

Author keywords

5 Azacytidine; Hypomethylating agents; Myelodysplastic syndrome; Randomized trials; Systematic review; Vidaza

Indexed keywords

AZA 001; AZACITIDINE; CYTARABINE; THALIDOMIDE; UNCLASSIFIED DRUG;

ANEMIA; CHEMOTHERAPY; DEATH; DISEASE CONTROL; GASTROINTESTINAL DISEASE; GRANULOCYTOPENIA; HUMAN; INFECTION; INJECTION SITE REACTION; LOW DRUG DOSE; META ANALYSIS; MORBIDITY; MYELODYSPLASTIC SYNDROME; NAUSEA AND VOMITING; OVERALL SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTOPENIA;

AGE FACTORS; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HUMANS; MYELODYSPLASTIC SYNDROMES; PRACTICE GUIDELINES AS TOPIC; QUALITY OF LIFE;

EID: 79151485927     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2010.05.006     Document Type: Review

References (41)

1. Brunning R., Bennett J., Flandrin G., et al. WHO classification of tumours: pathology and genetics of tumours of haematopoeitic and lymphoid tissues 2001, IARC Press, Lyon.
2. Bennett J.M., Catovsky D., Daniel M.T., et al. Proposals for the classification of the myelodysplastic syndromes. Brit J Haematol 1982, 51:189-199.
3. Aul C., Bowen D.T., Yoshida Y. Pathogenesis, etiology and epidemiology of myelodysplastic syndromes. Haematologica 1998, 83:71-86.
4. Aul C., Gattermann N., Schneider W. Epidemiological and etiological aspects of myelodysplastic syndromes. Leukemia Lymphoma 1995, 16:247-262.
5. Germing U., Aul C., Niemeyer C.M., Haas R., Bennett J.M. Epidemiology, classification and prognosis of adults and children with myelodysplastic syndromes. Ann Hematol 2008, 87:691-699.
6. List A.F., Vardiman J., Issa J.P., DeWitte T.M. Myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program 2004, 297-317.
7. Ma X., Does M., Raza A., Mayne S.T. Myelodysplastic syndromes: incidence and survival in the United States. Cancer 2007, 109:1536-1542.
8. Steensma D.P., Tefferi A. The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. Leukemia Res 2003, 27:95-120.
9. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10:223-232.
10. Silverman L.R., Demakos E.P., Peterson B.L., et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002, 20:2429-2440.
11. Silverman L.R., McKenzie D.R., Peterson B.L., et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006, 24:3895-3903.
12. Kornblith A.B., Herndon J.E., Silverman L.R., et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol 2002, 20:2441-2452.
13. Lyons R.M., Cosgriff T.M., Modi S.S., et al. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol 2009, 27:1850-1856.
14. Raza A., Mehdi M., Mumtaz M., Ali F., Lascher S., Galili N. Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia. Cancer 2008, 113:1596-1604.
15. Soriano A.O., Yang H., Faderl S., et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007, 110:2302-2308.
16. Nand S., Godwin J., Smith S., et al. Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial. Leukemia Lymphoma 2008, 49:2141-2147.
17. Marcucci G., Silverman L., Eller M., Lintz L., Beach C.L. Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes. J Clin Pharmacol 2005, 45:597-602.
18. Silverman L.R., Holland J.F., Weinberg R.S., et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia 1993, 7(Suppl. 1):21-29.
19. List A, Fenaux G, Mufti J, et al. Effect on overall survival in higher-risk myelodysplastic syndromes (MDS) without complete remission. In: J Clin Oncol; 2008.
20. Mufti G, Fenaux G, Hellstrom-Lindberg E, et al. Treatment of high-risk MDS patients (pts) with -7/del (7q) with azacitidine (AZA) versus conventional care regimens (CCR): effects on overall survival. In: J Clin Oncol: ASCO; 2008. p. 26 [abstract 7033].
21. Seymour J, Fenaux P, Silverman L, et al. Effects of azacitidine (AZA) vs conventional care regimens (CCR) in elderly (75 yrs) patients (Pts) with myelodysplastic syndromes (MDS) from the AZA-001 survival trial. In: ASH: Blood; 2008 [abstract 3629].
22. Fenaux G, Mufti G, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival (OS) and reduces infections and hospitalizations in patients (Pts) with WHO-defined acute myeloid leukemia (AML) compared with conventional care regimens (CCR). In: ASH, San Francisco: Blood; 2008 [abstract 3636].
23. Silverman L, Fenaux G, Mufti G, et al. The effects of continued azacitidine (AZA) treatment cycles on response in higher-risk patients (Pts) with myelodysplastic syndromes (MDS). In: ASH, San Francisco: Blood; 2008 [abstract 227].
24. Santini V, Fenaux G, Mufti G, et al. Management and supportive care measures of adverse events in higher risk MDS patients treated with azacitidine (AZA). In: Blood; 2008 [Abstract 1653].
25. Cheson B.D., Bennett J.M., Kantarjian H., et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000, 96:3671-3674.
26. Cheson B.D., Greenberg P.L., Bennett J.M., et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006, 108:419-425.
27. Greenberg P., Cox C., LeBeau M.M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
28. Cheson B.D. Standard and low-dose chemotherapy for the treatment of myelodysplastic syndromes. Leukemia Res 1998, 22(Suppl. 1):S17-S21.
29. Cheson B.D., Simon R. Low-dose ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes: a review of 20 years' experience. Semin Oncol 1987, 14:126-133.
30. Hellstrom-Lindberg E., Robert K.H., Gahrton G., et al. A predictive model for the clinical response to low dose ara-C: a study of 102 patients with myelodysplastic syndromes or acute leukaemia. Brit J Haematol 1992, 81:503-511.
31. Gajewski J.L., Ho W.G., Nimer S.D., et al. Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome. J Clin Oncol 1989, 7:1637-1645.
32. Verbeek W., Wormann B., Koch P., et al. S-HAM induction chemotherapy with or without GM-CSF in patients with high-risk myelodysplastic syndromes. Ann Hematol 1997, 74:205-208.
33. Estey E.H., Thall P.F., Cortes J.E., et al. Comparison of idarubicin+ara-C-, fludarabine+ara-C-, and topotecan+ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood 2001, 98:3575-3583.
34. de Witte T., Suciu S., Verhoef G., et al. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood 2001, 98:2326-2331.
35. Kantarjian H., O'Brien S., Cortes J., et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 2006, 106:1090-1098.
36. Knipp S., Hildebrand B., Kundgen A., et al. Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes. Cancer 2007, 110:345-352.
37. Hofmann W.K., Heil G., Zander C., et al. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia. Ann Hematol 2004, 83:498-503.
38. Cutler C.S., Lee S.J., Greenberg P., et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004, 104:579-585.
39. Barrett A.J., Savani B.N. Allogeneic stem cell transplantation for myelodysplastic syndrome. Semin Hematol 2008, 45:49-59.
40. Burnett A., Milligan D., Prentic A., et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 2007, 109:1114-1124.
41. Brechignac S, Hellstrom-Lindberg E, Bowen DT, DeWitt TM, Cazzola M, Fenaux P. Quality of life and economic impact of red blood cell (RBC) transfusions on patients with myelodysplastic syndromes (MDS) In: ASH: Blood; 2004. p. 263b.